STAT+: In study, Gilead’s Trodelvy shows modest benefit in breast cancer patients
The cancer drug Trodelvy reduced the risk of tumors progressing by 34% compared to chemotherapy in patients with the most common form of metastatic breast cancer.
News
STAT+: Gilead drug prolongs survival of women with common form of breast cancer
Gilead Sciences said its cancer drug Trodelvy prolonged the survival of women with the most common form of breast cancer by just under 30%. […]
News
STAT+: General Catalyst, Andreessen Horowitz bet on large language models for health care
In a rare partnership, heavyweight tech venture firms General Catalyst and Andreessen Horowitz are co-leading a $50 million seed round aimed at exploring large language models in health care. […]
News
STAT+: Pharmalittle: Senate delays PBM-reform bill effective date; Gilead and HHS square off in court over HIV patents
Pharmacy benefit managers may have gotten themselves a slight reprieve: Senators drafting reforms delayed their effective date by at least 10 months. […]
